Synthesis and biological evaluation of primaquine–chloroquine twin drug: a novel heme-interacting molecule prevents free heme and hydroxyl radical-mediated protein degradation
作者:Chinmay Pal、Souvik Sarkar、Somnath Mazumder、Susanta Adhikari、Uday Bandyopadhyay
DOI:10.1039/c3md00019b
日期:——
Accumulations of oxidized and degraded proteins are the markers for oxidative stress. Degradation of hemoprotein e.g. hemoglobin during different pathological conditions produces heme, which induces oxidative stress and inflammation through its pro-oxidant nature and leads to protein degradation. Moreover reduced transition-metal ions Fe2+ can generate toxic hydroxyl radicals (ËOH) and leads to protein degradation. Therefore, synthesis of a compound that will detoxify free heme, chelate Fe+2 and show antioxidant activity by scavenging ËOH would be beneficial against protein degradation. Here, we report the synthesis of a novel heme-interacting primaquineâchloroquine twin drug (PQCL) that could chelate free iron and showed excellent antioxidant activity as evident from ferric reducing antioxidant power. PQCL prevented ËOH and heme-mediated protein degradation. PQCL also could scavenge nitrogen-centered free radical (2,2-diphenyl-1-picrylhydrazyl). Thus, we have synthesized PQCL, a heme-interacting molecule, which is capable to prevent free heme and ËOH-mediated protein degradation.
氧化和降解蛋白质的积累是氧化应激的标志。在不同的病理条件下,血蛋白(如血红蛋白)降解会产生血红素,血红素具有促氧化作用,会诱发氧化应激和炎症,导致蛋白质降解。此外,还原过渡金属离子 Fe2+ 可产生有毒的羟自由基(ËOH),导致蛋白质降解。因此,合成一种能解毒游离血红素、螯合 Fe+2 并通过清除 ËOH 而显示抗氧化活性的化合物将有利于防止蛋白质降解。在此,我们报告了一种新型血红素相互作用的伯氨喹-氯喹孪生药物(PQCL)的合成过程,这种药物可以螯合游离铁,并通过铁还原抗氧化能力显示出卓越的抗氧化活性。PQCL 可防止ËOH 和血红素介导的蛋白质降解。PQCL 还能清除以氮为中心的自由基(2,2-二苯基-1-苦基肼)。因此,我们合成了一种与血红素相互作用的分子--PQCL,它能够防止游离血红素和ËOH介导的蛋白质降解。